Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Overview
This study explores generating banked SARS-CoV-2-specific virus-specific T cells (VSTs) for immunocompromised patients. The manufacturing process utilized G-Rex® devices with activating cytokines to produce Th1-polarized, polyfunctional T cells capable of selectively killing viral antigen-expressing targets.
What this paper found
Virus-specific T cells generated from convalescent donors with mild COVID-19 selectively killed targets expressing SARS-CoV-2 antigens, supporting a banked, off-the-shelf product for high-risk patients. Donor cells were screened against peptide libraries covering 18 viral proteins, and eight immunodominant targets were chosen for manufacturing in a G-Rex® device with activating cytokines. Cells expanded a mean 29-fold (n=5) and were 97.1% CD3+, mostly CD4+ helper (85.5%) with 10.2% CD8+. All lines responded to the target antigens by IFNγ ELISpot, were Th1-polarized, and killed pepmix-loaded autologous PHA blasts without auto- or alloreactivity. The authors are advancing the product toward a randomized clinical trial in hospitalized high-risk patients.
Note: Preclinical, in vitro characterization of the cells; the authors state that the product is being advanced to a randomized clinical trial.
SARS-CoV-2 VSTs generated from convalescent individuals are Th1-polarized, polyfunctional and selectively able to kill viral antigen-expressing targets with no auto- or alloreactivity, indicative of both their selectivity and safety for clinical use. — Spyridoula Vasileiou, Manik Kuvalekar, Aster Workineh, Ayumi Watanabe, Yovana Velazquez, Suhasini Lulla, Helen E. Heslop, Kimberly Mooney, Kevin Grimes, George Carrum, LaQuisa C. Hill, Premal Lulla, Ann M. Leen, Blood
Study details
- Authors
- Spyridoula Vasileiou, Manik Kuvalekar, Aster Workineh, Ayumi Watanabe, Yovana Velazquez, Suhasini Lulla, Helen E. Heslop, Kimberly Mooney, Kevin Grimes, George Carrum, LaQuisa C. Hill, Premal Lulla, Ann M. Leen
- Institution
- Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USA · AlloVir, Houston, TX, USA · Houston Methodist Hospital, Houston, TX, USA
- Journal
- Blood
- Year
- 2020
- PMID / PMC
- PMC
- Cell type(s)
- VST Cells
- Application area
- Infectious disease
- Study phase
- Preclinical
How G-Rex® was used
Cells from convalescent donors were cultured in a G-Rex® device in medium supplemented with activating cytokines to generate SARS-CoV-2-specific T cells directed against eight immunodominant viral antigens. Across five lines, the culture produced a mean 29-fold expansion of cells that were almost entirely CD3+ T cells.
Explore related
Full citation
Vasileiou S, Kuvalekar M, Workineh A, et al. Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19. Blood. 2020;136(Supplement 1):5-5.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.